Metis TechBio Co., Ltd. (SEHK: 7666)
Salud · Biotecnología · CN
8,36 HK$
-19,69 % hoy · -64,9 % 1 año
Metis TechBio Co., Ltd. (SEHK: 7666) opera en la industria de biotecnología dentro del sector salud. Su valor en bolsa es de 1,26 mil M $ y tiene 150 empleados.
En los últimos doce meses la acción ha bajado un 64,9 % y ha cotizado entre 8,36 y 29,98.
Tweenvest puntúa a Metis TechBio Co., Ltd. en cuatro factores: calidad 49/100, valor 67/100. Su punto más fuerte es valor.
Evolución de la cotización de 7666
Cifras clave
- Capitalización
- 1,26 mil M $
- Ingresos (últ. 12 m)
- 38,00 M $
- PER
- -15,33
- BPA
- -4,63
- Rent. por dividendo
- —
- Beta (5 años)
- —
- Máximo 52 semanas
- 29,98 HK$
- Mínimo 52 semanas
- 8,36 HK$
- Volumen medio (3 m)
- —
- Acciones en circulación
- 1,18 mil M
- Empleados
- 150
- Próximos resultados
- —
Sobre Metis TechBio Co., Ltd.
Metis TechBio Co., Ltd., founded in 2020 and headquartered in Beijing, China, (previously Hangzhou Jitai Pharmaceutical Technology Co., Ltd.) specializes in the advanced research and development of AI-powered nanomaterials. The company's core mission is to facilitate the delivery and application of active agents within carbon-based life forms, operating in both the Chinese Mainland and the United States. Central to its offerings is NanoForge, a comprehensive suite of interconnected technologies that includes a novel lipid library, foundational artificial intelligence models, METiSAIAgent, cutting-edge quantum chemistry and molecular dynamics simulations, and AI-driven screening platforms. Furthermore, Metis TechBio has developed specialized platforms like AiTEM, AiLNP, and AiRNA. These tools are crucial for simulating, predicting, and interpreting interactions at the nanoscale, thereby enabling the precise design, optimization, and validation of sophisticated nanomaterials and their associated payloads. The company provides its services through a three-tiered system: a foundational dry-wet data layer supported by integrated laboratory infrastructure, a model layer featuring METiS AI foundational models, and an application layer known as METiSAgentv. Metis TechBio primarily serves a diverse clientele, including pharmaceutical companies, biotechnology firms, and medical research institutions.
- ISIN
- CNE100007LD1
- Fundada en
- 2020
- Cotiza desde
- 13 may 2026
- Bolsa
- The Stock Exchange of Hong Kong Ltd.
- Divisa
- HKD
Otras empresas de biotecnología
| Empresa | Capitalización | Precio | Día |
|---|---|---|---|
| UroGen Pharma Ltd.NasdaqGM: URGN | 1,29 mil M $ | 26,39 $ | +1,11 % |
| Mineralys Therapeutics, Inc.NasdaqGS: MLYS | 1,28 mil M $ | 14,48 $ | -0,34 % |
| Savara Inc.NasdaqGS: SVRA | 1,27 mil M $ | 4,72 $ | +5,36 % |
| Pacific Shuanglin Bio-pharmacy Co., Ltd.SZSE: 000403 | 1,26 mil M $ | 8,99 CN¥ | -0,66 % |
| Idorsia LtdSWX: IDIA | 1,26 mil M $ | 3,91 CHF | -1,06 % |
| Hualan Biological Vaccine Inc.SZSE: 301207 | 1,25 mil M $ | 14,05 CN¥ | -1,75 % |
| BioGaia AB (publ)OM: BIOG B | 1,25 mil M $ | 125,60 Skr | +0,24 % |
| Silence Therapeutics plcNasdaqGM: SLN | 1,23 mil M $ | 19,83 $ | +0,15 % |